Skip to main content
. Author manuscript; available in PMC: 2013 Nov 11.
Published in final edited form as: Leukemia. 2012 Jul 13;27(1):10.1038/leu.2012.191. doi: 10.1038/leu.2012.191

Figure 4.

Figure 4

FLT3 signaling remains intact in some resistant mutants when treated with a FLT3 tyrosine kinase inhibitor. BaF3 FLT3/ITD cells expressing the unmutated ITD, the F621L/ITD, the A627P/ITD, the F691L/ITD or the Y842C/ITD mutation were treated with the indicated concentrations of FLT3 TKI for 1 h. Cells were lysed in NP-40 buffer for 30 mins on ice, Lysates were separated on 8% SDS-PAGE gels, transferred to polyvinyl diflouride membranes using antibodies for pSTAT5, pAKT, pMAPK and their total protein counterparts and analyzed by enhanced chemiluminescence.